Actively Recruiting
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2025-12-03
84
Participants Needed
2
Research Sites
101 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the pharmacokinetics, radiation dosimetry, safety and preliminary efficacy of HRS-6768. To explore the reasonable dosage of HRS-6768 in the treatment of patients with advanced solid tumors.
CONDITIONS
Official Title
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to provide a written informed consent
- Diagnosed with advanced-stage (unresectable or metastatic) solid tumors confirmed by histology or cytology
- Have failed standard treatment due to disease progression or intolerance, or lack effective treatment options
- Have at least one measurable lesion
- Have an ECOG performance status of 0-1
- Have good functioning of major organs
You will not qualify if you...
- Experienced significant weight loss within 28 days before signing informed consent
- Previously received radiopharmaceutical therapy, radioactive embolization, or external beam radiotherapy involving more than 25% of bone marrow
- Previously had external beam radiotherapy directly to kidneys or any external beam radiotherapy within 2 weeks before first dose
- Received anti-tumor treatments such as surgery (excluding biopsy and drainage), checkpoint inhibitors, antibody therapies, chemotherapy, targeted therapy, gene therapy, or vaccines within 4 weeks before first dose
- Had severe infection (CTCAE Grade >2) requiring hospitalization or infectious complications within 4 weeks before first dose
- Had symptoms or signs of infection requiring intravenous antibiotics (excluding prophylactic use) within 2 weeks before first dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Beijing Gaobo Hospital
Beijing, Beijing Municipality, China, 102206
Actively Recruiting
2
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
Z
Zengquan Gu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here